Shares of Novavax Inc (NVAX) surged 6.63% in Wednesday's intraday trading session, as the biotechnology company announced the sale of its manufacturing facility in Bohumil, Czech Republic, to Danish pharmaceutical giant Novo Nordisk for $200 million.
According to reports, Novavax intends to utilize the proceeds from this divestment to fund its vaccine pipeline development. The sale comes as Novavax aims to focus its resources on its core vaccine business and streamline operations following the COVID-19 pandemic.
Investors reacted positively to the news, viewing the sale as a strategic move that will provide Novavax with additional capital to advance its promising vaccine candidates. The company's decision to divest a non-core asset was seen as a step towards strengthening its financial position and concentrating on its core competencies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。